An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis
出版年份 2022 全文链接
标题
An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis
作者
关键词
-
出版物
Journal of Infection and Public Health
Volume 15, Issue 10, Pages 1097-1107
出版商
Elsevier BV
发表日期
2022-09-02
DOI
10.1016/j.jiph.2022.08.016
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis
- (2022) Xi Chen et al. CURRENT MICROBIOLOGY
- Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents
- (2022) Rui Shi et al. ACS Medicinal Chemistry Letters
- QcrB in Mycobacterium tuberculosis : The new drug target of antitubercular agents
- (2021) Aparna Bahuguna et al. MEDICINAL RESEARCH REVIEWS
- Synthetic molecules as DprE1 inhibitors: A patent review
- (2021) Mohd. Imran et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts
- (2021) Jeremiah Chakaya et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Synthesis and recycling of the mycobacterial cell envelope
- (2021) Katherine A Abrahams et al. CURRENT OPINION IN MICROBIOLOGY
- Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832
- (2021) Gregory T. Robertson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
- (2021) Mohd. Imran et al. Journal of Infection and Public Health
- Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence
- (2021) Sonali Chhabra et al. ACS Omega
- Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
- (2021) Mohd. Imran et al. Pharmaceuticals
- Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
- (2021) Mohd. Imran et al. MOLECULES
- Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy
- (2021) Wenping Gong et al. Frontiers in Microbiology
- New tuberculosis drug targets, their inhibitors, and potential therapeutic impact
- (2020) Gauri S. Shetye et al. Translational Research
- Development of Macozinone for TB treatment: An Update
- (2020) Vadim Makarov et al. Applied Sciences-Basel
- Diagnostic Potential of IgG and IgA Responses to Mycobacterium tuberculosis Antigens for Discrimination among Active Tuberculosis, Latent Tuberculosis Infection, and Non-Infected Individuals
- (2020) Ji Yeon Lee et al. Microorganisms
- Macozinone: revised synthesis and crystal structure of a promising new drug for treating drug-sensitive and drug-resistant tuberculosis
- (2019) Gang Zhang et al. Acta Crystallographica Section C-Structural Chemistry
- A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis
- (2019) Karen Cohen et al. Expert Opinion On Drug Safety
- Pretomanid: First Approval
- (2019) Susan J. Keam DRUGS
- Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development
- (2019) Tiago Beites et al. Nature Communications
- Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis
- (2018) Jérémie Piton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug targets exploited in Mycobacterium tuberculosis : Pitfalls and promises on the horizon
- (2018) Zubair Shanib Bhat et al. BIOMEDICINE & PHARMACOTHERAPY
- Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1): challenging target for antitubercular drug discovery
- (2018) Jineetkumar Gawad et al. Chemistry Central Journal
- Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
- (2018) André Campaniço et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Expanding Benzoxazole-Based Inosine 5′-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure–Activity As Potential Antituberculosis Agents
- (2018) Shibin Chacko et al. JOURNAL OF MEDICINAL CHEMISTRY
- Central Nervous System Tuberculosis
- (2018) Martin Alexander Schaller et al. Clinical Neuroradiology
- Tuberculosis treatment
- (2017) Marcelo Fouad Rabahi et al. Jornal Brasileiro de Pneumologia
- A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells
- (2017) Paridhi Sukheja et al. mBio
- Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions
- (2017) Tiansheng Wang et al. ACS Medicinal Chemistry Letters
- New agents for the treatment of drug-resistant Mycobacterium tuberculosis
- (2016) Daniel T. Hoagland et al. ADVANCED DRUG DELIVERY REVIEWS
- Exploring the structure of glutamate racemase from Mycobacterium tuberculosis as a template for anti-mycobacterial drug discovery
- (2016) S. Poen et al. BIOCHEMICAL JOURNAL
- Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ
- (2016) Krupanandan Haranahalli et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase
- (2016) Shilah A. Bonnett et al. ACS Infectious Diseases
- Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis
- (2015) Benoit Lechartier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Traitement de la tuberculose
- (2015) J. Ben Amar et al. Revue de Pneumologie Clinique
- DprE1 - from the Discovery to the Promising Tuberculosis Drug Target
- (2014) Katarina Miku.sova et al. CURRENT PHARMACEUTICAL DESIGN
- Towards a new combination therapy for tuberculosis with next generation benzothiazinones
- (2014) V. Makarov et al. EMBO Molecular Medicine
- The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
- (2013) Giovanna Riccardi et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Structural Basis for the Recognition of Mycolic Acid Precursors by KasA, a Condensing Enzyme and Drug Target fromMycobacterium Tuberculosis
- (2013) Johannes Schiebel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis
- (2013) Regina Wilson et al. Nature Chemical Biology
- Treatment of latent tuberculosis infection
- (2013) Madhavi J. Parekh et al. Therapeutic Advances in Respiratory Disease
- RETRACTED ARTICLE: Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1: state of art
- (2012) Silvia Buroni et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
- (2012) Myungsun Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones
- (2010) M. R. Pasca et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel targets in M. tuberculosis: search for new drugs
- (2010) Gyanu Lamichhane TRENDS IN MOLECULAR MEDICINE
- Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
- (2009) V. Makarov et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now